Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation

Table 4

Recovery studies^a.

Label claim	Amount of drug added (%)	Total amount of drug present μg/mL	Amount found μg/mL	% Recovery ± SD
		T-I
300 mg	80	10800	10733.04	99.38±0.82
	100	12000	11941.2	99.51±0.23
	120	13200	13101	99.25±0.63
		T-II
300 mg	80	10800	10725.48	99.31±0.22
	100	12000	11980.8	99.84±0.30
	120	13200	13082.52	99.11±0.75

^a𝑛=6.